Literature DB >> 32755425

Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development.

Sayeh Ezzikouri1,2, Jalal Nourlil3, Soumaya Benjelloun1, Michinori Kohara4, Kyoko Tsukiyama-Kohara2.   

Abstract

The current Coronavirus Disease 2019 (COVID-19) pandemic is causing great alarm around the world. The pathogen for COVID-19 - severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - is the seventh known coronavirus to cause pneumonia in humans. While much remains unknown about SARS-CoV-2, physicians and researchers have begun to publish relevant findings, and much evidence is available on coronaviruses previously circulating in human and animal populations. In this review, we situate COVID-19 in its context as a transboundary viral disease, and provide a comprehensive discussion focused on the discovery, spread, virology, pathogenesis, and clinical features of this disease, its causative coronaviral pathogen, and approaches to combating the disease through immunotherapies and other treatments and vaccine development. An epidemiological survey revealed a potentially large number of asymptomatic SARS-CoV-2 carriers within the population, which may hamper efforts against COVID-19. Finally, we emphasize that vaccines against SARS-CoV-2, which may be developed by 2021, will be essential for prevention of COVID-19.

Entities:  

Keywords:  Human coronavirus; origin; pathogenesis; public health; respiratory viruses; sars-CoV-2

Year:  2020        PMID: 32755425     DOI: 10.1080/21645515.2020.1787068

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  4 in total

1.  Absence of Anti-RBD Antibodies in SARS-CoV-2 Infected or Naive Individuals Prior to Vaccination with CoronaVac Leads to Short Protection of Only Four Months Duration.

Authors:  Camille F de Oliveira; Walter F F Neto; Carla P da Silva; Ana Claudia S Ribeiro; Lívia C Martins; Alana W de Sousa; Maria N O Freitas; Jannifer O Chiang; Franko A Silva; Eder B Dos Santos; Daniele B A Medeiros; Gleiciane S Pinheiro; Gleiciane F Brandão; Valéria L Carvalho; Raimunda S S Azevedo; Pedro F C Vasconcelos; Igor B Costa; Iran B Costa; Mirleide C Dos Santos; Luana S Soares; Rayssa L S Bedran; James L Ferreira; Alberto A Amarilla; Naphak Modhiran; Christopher L D McMillan; Morgan E Freney; David A Muller; Daniel Watterson; Lívia M N Casseb; Daniele F Henriques
Journal:  Vaccines (Basel)       Date:  2022-04-28

2.  Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals.

Authors:  Susan L Uprichard; Amornrat O'Brien; Monika Evdokimova; Cynthia L Rowe; Cara Joyce; Matthew Hackbart; Yazmin E Cruz-Pulido; Courtney A Cohen; Michelle L Rock; John M Dye; Paul Kuehnert; Keersten M Ricks; Marybeth Casper; Lori Linhart; Katrina Anderson; Laura Kirk; Jack A Maggiore; Andrew S Herbert; Nina M Clark; Gail E Reid; Susan C Baker
Journal:  Viruses       Date:  2022-02-10       Impact factor: 5.048

3.  Plant-derived compounds effectively inhibit the main protease of SARS-CoV-2: An in silico approach.

Authors:  Shafi Mahmud; Shamima Afrose; Suvro Biswas; Abir Nagata; Gobindo Kumar Paul; Mohasana Akter Mita; Md Robiul Hasan; Mst Sharmin Sultana Shimu; Shahriar Zaman; Md Salah Uddin; Md Sayeedul Islam; Md Abu Saleh
Journal:  PLoS One       Date:  2022-08-23       Impact factor: 3.752

4.  Saliva specimens for detection of severe acute respiratory syndrome coronavirus 2 in Kuwait: A cross-sectional study.

Authors:  Haya Altawalah; Fatma AlHuraish; Wafaa Ali Alkandari; Sayeh Ezzikouri
Journal:  J Clin Virol       Date:  2020-10-01       Impact factor: 3.168

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.